Top-Rated StocksTop-RatedNASDAQ:EXEL Exelixis (EXEL) Stock Forecast, Price & News $19.35 +0.08 (+0.42%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$19.22▼$19.6050-Day Range$18.17▼$20.4852-Week Range$14.87▼$22.47Volume1.53 million shsAverage Volume2.90 million shsMarket Capitalization$6.30 billionP/E Ratio40.31Dividend YieldN/APrice Target$25.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exelixis MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside30.9% Upside$25.33 Price TargetShort InterestHealthy2.28% of Shares Sold ShortDividend StrengthN/ASustainability-1.63Upright™ Environmental ScoreNews Sentiment1.01Based on 6 Articles This WeekInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings Growth50.77%From $0.65 to $0.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.11 out of 5 starsMedical Sector12th out of 981 stocksBiological Products, Except Diagnostic Industry3rd out of 163 stocks 3.4 Analyst's Opinion Consensus RatingExelixis has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.33, Exelixis has a forecasted upside of 30.9% from its current price of $19.35.Amount of Analyst CoverageExelixis has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.28% of the outstanding shares of Exelixis have been sold short.Short Interest Ratio / Days to CoverExelixis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exelixis has recently increased by 21.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExelixis does not currently pay a dividend.Dividend GrowthExelixis does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExelixis has received a 64.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "VEGFR tyrosine kinase inhibitors", "Mitogen-activated protein kinase (MEK) inhibitors", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Exelixis is -1.63. Previous Next 2.2 News and Social Media Coverage News SentimentExelixis has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exelixis this week, compared to 7 articles on an average week.Search InterestOnly 11 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,033,122.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Exelixis is held by insiders.Percentage Held by Institutions84.74% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Exelixis are expected to grow by 50.77% in the coming year, from $0.65 to $0.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exelixis is 40.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Exelixis is 40.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.01.Price to Earnings Growth RatioExelixis has a PEG Ratio of 0.82. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioExelixis has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exelixis (NASDAQ:EXEL) StockExelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.Read More Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Stock News HeadlinesMay 18, 2023 | marketbeat.comAnalysts Say These 2 Mid-Cap Biotechs Have 2x Potential (EXEL)These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.June 8, 2023 | finance.yahoo.comWhy Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?June 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 6, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Exelixis (EXEL)May 31, 2023 | bizjournals.comFarallon lands three directors on Exelixis board to push for changesMay 31, 2023 | finance.yahoo.comFarallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ BoardMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Exelixis (EXEL)May 29, 2023 | finance.yahoo.comExelixis, Inc.'s (NASDAQ:EXEL) market cap decline of US$208m may not have as much of an impact on institutional owners after a year of 4.0% returnsJune 8, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 28, 2023 | msn.comExelixis: Thriving Investment Opportunity In The Evolving World Of OncologyMay 26, 2023 | americanbankingnews.comExelixis, Inc. to Post Q4 2024 Earnings of $0.29 Per Share, Zacks Research Forecasts (NASDAQ:EXEL)May 25, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Exelixis, Inc. (NASDAQ:EXEL) Cut by AnalystMay 22, 2023 | americanbankingnews.comExelixis (NASDAQ:EXEL) Now Covered by Analysts at StockNews.comMay 21, 2023 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 17, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Exelixis (EXEL), Masimo (MASI) and Reata Pharmaceuticals (RETA)May 16, 2023 | seekingalpha.comExelixis: If It Ain't Broke...May 16, 2023 | morningstar.comExelixis Inc EXEL Stock QuoteMay 16, 2023 | fool.comExelixis (NASDAQ: EXEL)May 12, 2023 | finance.yahoo.comExelixis, Inc. (NASDAQ:EXEL) Shares Could Be 49% Below Their Intrinsic Value EstimateMay 12, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Exelixis (EXEL)May 11, 2023 | msn.comJMP Securities Reiterates Exelixis (EXEL) Market Outperform RecommendationMay 11, 2023 | americanbankingnews.comExelixis (NASDAQ:EXEL) Price Target Increased to $21.00 by Analysts at Stifel NicolausMay 10, 2023 | sfgate.comExelixis: Q1 Earnings SnapshotMay 10, 2023 | markets.businessinsider.comExelixis (EXEL) Receives a New Rating from Piper SandlerMay 10, 2023 | msn.comExelixis board member resigns; Farallon gets third board seat in victoryMay 10, 2023 | markets.businessinsider.com8 Analysts Have This to Say About ExelixisMay 10, 2023 | finance.yahoo.comExelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/YSee More Headlines EXEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXEL Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXEL CUSIP30161Q10 CIK939767 Webwww.exelixis.com Phone(650) 837-7000Fax650-837-8300Employees1,223Year Founded1994Price Target and Rating Average Stock Price Forecast$25.33 High Stock Price Forecast$32.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+31.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.48 Trailing P/E Ratio40.19 Forward P/E Ratio29.68 P/E Growth0.82Net Income$182.28 million Net Margins9.24% Pretax Margin11.86% Return on Equity6.20% Return on Assets5.10% Debt Debt-to-Equity RatioN/A Current Ratio5.00 Quick Ratio4.91 Sales & Book Value Annual Sales$1.61 billion Price / Sales3.90 Cash Flow$0.62 per share Price / Cash Flow31.14 Book Value$7.68 per share Price / Book2.51Miscellaneous Outstanding Shares325,600,000Free Float316,158,000Market Cap$6.28 billion OptionableOptionable Beta0.68 Social Links Key ExecutivesMichael M. MorrisseyPresident, Chief Executive Officer & DirectorChristopher J. SennerChief Financial Officer & Executive Vice PresidentDana AftabChief Scientific Officer & Executive VP-DiscoveryVicki L. GoodmanChief Medical Officer & Executive Vice PresidentJeffrey J. HessekielSecretary, Executive VP & General CounselKey CompetitorsHalozyme TherapeuticsNASDAQ:HALONeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENBioCryst PharmaceuticalsNASDAQ:BCRXCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 102,835 shares on 6/1/2023Ownership: 0.095%Ontario Teachers Pension Plan BoardBought 3,280 shares on 6/1/2023Ownership: 0.020%ProShare Advisors LLCSold 9,692 shares on 5/26/2023Ownership: 0.013%Brandywine Global Investment Management LLCBought 893,848 shares on 5/25/2023Ownership: 0.275%Toroso Investments LLCBought 9,518 shares on 5/23/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions EXEL Stock - Frequently Asked Questions Should I buy or sell Exelixis stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXEL shares. View EXEL analyst ratings or view top-rated stocks. What is Exelixis' stock price forecast for 2023? 8 Wall Street analysts have issued twelve-month price objectives for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they predict the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 30.0% from the stock's current price. View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts. How have EXEL shares performed in 2023? Exelixis' stock was trading at $16.04 at the beginning of 2023. Since then, EXEL shares have increased by 21.5% and is now trading at $19.49. View the best growth stocks for 2023 here. Are investors shorting Exelixis? Exelixis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,410,000 shares, an increase of 21.5% from the April 30th total of 6,100,000 shares. Based on an average trading volume of 3,050,000 shares, the days-to-cover ratio is presently 2.4 days. View Exelixis' Short Interest. When is Exelixis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our EXEL earnings forecast. How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by $0.05. The biotechnology company earned $408.79 million during the quarter, compared to analyst estimates of $427.91 million. Exelixis had a net margin of 9.24% and a trailing twelve-month return on equity of 6.20%. What ETFs hold Exelixis' stock? ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), First Trust Health Care AlphaDEX Fund (FXH), ERShares Entrepreneurs ETF (ENTR), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Invesco S&P MidCap Quality ETF (XMHQ). What guidance has Exelixis issued on next quarter's earnings? Exelixis issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.77 billion-$1.88 billion, compared to the consensus revenue estimate of $1.83 billion. What is Michael M. Morrissey's approval rating as Exelixis' CEO? 75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend. What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV). What is Exelixis' stock symbol? Exelixis trades on the NASDAQ under the ticker symbol "EXEL." Who are Exelixis' major shareholders? Exelixis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.14%), Farallon Capital Management LLC (7.22%), Renaissance Technologies LLC (4.70%), State Street Corp (3.98%), JPMorgan Chase & Co. (2.38%) and Price T Rowe Associates Inc. MD (1.85%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends. How do I buy shares of Exelixis? Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exelixis' stock price today? One share of EXEL stock can currently be purchased for approximately $19.49. How much money does Exelixis make? Exelixis (NASDAQ:EXEL) has a market capitalization of $6.35 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.48 on an earnings per share basis. How many employees does Exelixis have? The company employs 1,223 workers across the globe. How can I contact Exelixis? Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300. This page (NASDAQ:EXEL) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.